NCT01965223View on ClinicalTrials.gov

A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung (TROG 13.01 SAFRON II)

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 4, 2015

Primary Completion Date

July 27, 2020

Study Completion Date

July 27, 2020

Conditions
CancerMetastases to the Lung
Interventions
RADIATION

Multi-fraction SABR

Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.

RADIATION

Single Fraction SABR

Single fraction SABR; 28Gy delivered in 1 fraction

Trial Locations (9)

2031

Prince of Wales Hospital, Randwick

2065

Northern Sydney Cancer Centre (RNS), St Leonards

2170

Liverpool Hospital, Liverpool

2298

Calvary Mater Hospital, Newcastle

2560

Cambelltown Hospital, Sydney

3002

Peter MacCallum Cancer Center, Melbourne

4102

Princess Alexandra Hospital, Woolloongabba

5000

Royal Adelaide Hospital, Adelaide

6009

Sir Charles Gairdner Hospital, Nedlands

All Listed Sponsors
collaborator

Australasian Lung Cancer Trials Group

OTHER

lead

Trans Tasman Radiation Oncology Group

OTHER

NCT01965223 - A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung (TROG 13.01 SAFRON II) | Biotech Hunter | Biotech Hunter